Your browser doesn't support javascript.
loading
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma.
Blommestein, Hedwig M; Franken, Margreet G; van Beurden-Tan, Chrissy H Y; Blijlevens, Nicole M A; Huijgens, Peter C; Sonneveld, Pieter; Uyl-de Groot, Carin A; Zweegman, Sonja.
Affiliation
  • Blommestein HM; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
  • Franken MG; Institute of Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
  • van Beurden-Tan CHY; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • Blijlevens NMA; Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Huijgens PC; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Sonneveld P; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • Uyl-de Groot CA; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
  • Zweegman S; Institute of Medical Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, the Netherlands.
JAMA Netw Open ; 4(3): e213497, 2021 03 01.
Article in En | MEDLINE | ID: mdl-33779744

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / Quality-Adjusted Life Years / Clinical Decision-Making / Multiple Myeloma / Antineoplastic Agents Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: JAMA Netw Open Year: 2021 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Organ Transplantation / Quality-Adjusted Life Years / Clinical Decision-Making / Multiple Myeloma / Antineoplastic Agents Type of study: Health_economic_evaluation / Observational_studies / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: JAMA Netw Open Year: 2021 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos